Fly News Breaks for April 2, 2019
Apr 2, 2019 | 07:22 EDT
Barclays analyst Gena Wang raised her price target for BioCryst Pharmaceuticals to $8 from $6 following a deep dive ahead of the BCX7353 APeX-2 Phase 3 readout in Q2 for the prevention of hereditary angioedema attacks. The analyst believes APeX-2 is "well powered to allow for statistical significance" with only greater than 25-30% attack reduction. However, she continues to see some risk in the trial outcome and a high bar for future commercial uptake. Wang keeps an Equal Weight rating on BioCryst.
News For BCRX From the Last 2 Days
There are no results for your query BCRX